Evaluation of depressive mood and cognitive functions in patients with acromegaly under somatostatin analogue therapy.


Alibas H., Uluc K. , Koytak P. , Uygur M. M. , Tuncer N. , Tanridag T. , ...More

Journal of endocrinological investigation, vol.40, no.12, pp.1365-1372, 2017 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 12
  • Publication Date: 2017
  • Doi Number: 10.1007/s40618-017-0722-y
  • Title of Journal : Journal of endocrinological investigation
  • Page Numbers: pp.1365-1372
  • Keywords: Acromegaly, Depressive mood, Cognitive functions, QUALITY-OF-LIFE, GROWTH-FACTOR-I, LONG-TERM CURE, PITUITARY-TUMORS, HORMONE EXCESS, RADIOTHERAPY, IMPAIRMENT, BRAIN, COMPLICATIONS, DYSFUNCTION

Abstract

Aims Acromegaly is caused by a pituitary adenoma that releases excess growth hormone (GH) and a concomitant increase in insulin-like growth factor 1 (IGF-1). Acromegaly results not only in phenotypic changes, but also in neurologic complications as peripheral neuropathy and cognitive dysfunction. This study aimed to compare depressive mood and cognitive function in patients with acromegaly and in healthy controls as well as to determine the factors underlying cognitive dysfunction in the acromegalic patients.